EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy of a K + Channel Agonist, XEN1101 , For Preserving Contractility in Mouse Models of Hypokalemic Periodic Paralysis

Viktor Chanchykov, Sharon Iype, Marbella Quinonez, Fenfen Wu, Stephen Cannon iD

Muscle & Nerve · 2026

DOI: 10.1002/mus.70159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Muscle & Nerve, 2026. Verfasst von Viktor Chanchykov und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Muscle Contraction, Hypokalemic Periodic Paralysis, Carbamates, Phenylenediamines. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aims Effective management remains lacking for recurrent episodes of acute weakness in hypokalemic periodic paralysis (HypoPP). We assessed the efficacy of a second‐generation potassium channel agonist, XEN1101, to prevent and abort the low‐K + induced loss of force in mouse models of HypoPP.

Methods

An ex vivo contractility assay was used to interrogate the efficacy of XEN1101 for preserving contractile force and for enhancing recovery of force in the setting of a low‐K + challenge for HypoPP mice carrying the sodium channel Na V 1.4‐R669H or the calcium channel Ca V 1.1‐R528H mutations.

Results

The acute loss of force for HypoPP muscle, triggered by a 2 mM K + challenge, was prevented by low micromolar XEN1101, with an effective concentration of 0.30 μM for 50% protection. Application of 1 μM XEN1101, after the onset of 2 mM K + induced weakness, restored the peak contractile force (70%–100% of baseline).

Discussion

The K V 7 potassium channel agonist XEN1101 is effective as both a prophylactic agent and as abortive therapy for management of low‐K + induced weakness in murine models of HypoPP. XEN1101 is more potent than the first‐generation Kv7 agonist, retigabine, in our murine models of HypoPP and is also better tolerated in patients. These improvements provide a rationale for future clinical trials of XEN1101 in HypoPP patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscle ContractionHypokalemic Periodic ParalysisCarbamatesPhenylenediaminesPotassium ChannelsAnimalsMiceDisease Models, AnimalMaleCalcium Channels, L-TypeMice, TransgenicMuscle, SkeletalPotassium

Stichwörter der Autor:innen

KCNQKv7 potassium channelchannelopathymouse modelperiodic paralysisskeletal muscle

Substanzen

ezogabineCarbamatesPhenylenediaminesCalcium Channels, L-TypePotassium ChannelsPotassium

Autor:innen und Institutionen

  • Department of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

ORCID-Profile: Stephen Cannon

Förderung

  • NIAMS NIH HHS
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Chanchykov, V., Iype, S., Quinonez, M., Wu, F., & Cannon, S. (2026). Efficacy of a K + Channel Agonist, XEN1101 , For Preserving Contractility in Mouse Models of Hypokalemic Periodic Paralysis. Muscle & Nerve. https://doi.org/10.1002/mus.70159

Vancouver

Chanchykov V, Iype S, Quinonez M, Wu F, Cannon S. Efficacy of a K + Channel Agonist, XEN1101 , For Preserving Contractility in Mouse Models of Hypokalemic Periodic Paralysis. Muscle & Nerve. 2026. doi:10.1002/mus.70159

BibTeX
@article{Chanchykov2026,
  author = {Chanchykov, Viktor and Iype, Sharon and Quinonez, Marbella and Wu, Fenfen and Cannon, Stephen},
  title = {Efficacy of a K + Channel Agonist, XEN1101 , For Preserving Contractility in Mouse Models of Hypokalemic Periodic Paralysis},
  journal = {Muscle & Nerve},
  year = {2026},
  doi = {10.1002/mus.70159}
}
Kostenlos starten →